High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.
Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.
MSD is currently evaluating tulisokibart in six different indications following the drug’s discontinuation in SSc-ILD.
Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield. T
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
Moby summary of Merck & Co., Inc.'s Q2 2026 earnings call
Merck raises full-year guidance on robust KEYTRUDA and new product momentum, while navigating acquisition-related EPS impact and pipeline setbacks.
Gilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th
Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s
Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.
Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
By Michael Erman and Christy Santhosh Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck (NYSE:MRK) shares moved higher in pre-market trading after the pharmaceutical company reported second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year revenue guidance. Although Merck reduced its adjusted earnings outlook to reflect acquisition-related charges, investors welcomed the stronger-than-expected quarterly performance and improved sales forecast.
The pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16
Merck (MRK) delivered earnings and revenue surprises of +50.00% and +1.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- Merck reported significantly better-than-expected earnings for the second quarter, while narrowing and raising its full-year revenue outlook.
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The company expects the full year’s revenue to be around $66.8 billion, close to analysts’ estimates. Its non-GAAP loss of $0.13 per share was 49.5% above analysts’ consensus estimates.
Stock futures pointed to a strong opening Tuesday, a day after the Dow Jones Industrial Average set a new closing record, as Palantir led tech shares higher and oil prices fell further.
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.
Merck's new injectable version of Keytruda walloped sales expectations Tuesday, packing a $200 million-plus punch vs. Wall Street's forecasts.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
